小细胞膀胱癌患者经卡铂、依托泊苷和阿替利珠单抗治疗获得长期完全缓解。
Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab.
机构信息
Department of Urology, Isehara Kyodo Hospital, 345, Tanaka, Isehara, Kanagawa, 259-1142, Japan.
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
出版信息
BMC Urol. 2022 Nov 5;22(1):170. doi: 10.1186/s12894-022-01130-4.
BACKGROUND
Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based chemotherapy, which is usually used for extensive-disease SCLC).
CASE PRESENTATION
Herein, we report a case of a 71-year-old man with SCBC who underwent radical cystectomy and received adjuvant chemotherapy with gemcitabine and cisplatin. However, recurrent tumors were found 6 months postoperatively. The patient was then treated with carboplatin, etoposide, and atezolizumab and achieved complete response. He continues receiving maintenance therapy with atezolizumab monotherapy without any evidence of recurrence over the 12 months follow up.
CONCLUSION
To our knowledge, this is the first case of metastatic SCBC where carboplatin, etoposide, and atezolizumab achieved long-term complete response.
背景
小细胞膀胱癌（SCBC）是一种罕见且侵袭性强的恶性肿瘤，目前尚无既定的治疗指南。其治疗方案一直基于小细胞肺癌（SCLC）指南。转移性 SCBC 预后较差（即使接受铂类为基础的化疗，这通常用于广泛期 SCLC）。
病例介绍
本文报道了一例 71 岁男性 SCBC 患者，接受根治性膀胱切除术，并接受吉西他滨和顺铂辅助化疗。然而，术后 6 个月发现复发性肿瘤。随后，患者接受卡铂、依托泊苷和阿替利珠单抗治疗，并获得完全缓解。在 12 个月的随访中，他继续接受阿替利珠单抗单药维持治疗，无复发迹象。
结论
据我们所知，这是首例转移性 SCBC 患者接受卡铂、依托泊苷和阿替利珠单抗治疗获得长期完全缓解的病例。
Zotero 插件